Japan Chemical Research Licenses Erythropoietin Rights To GSK
This article was originally published in PharmAsia News
Japan Chemical Research announced Dec. 18 a licensing agreement with GlaxoSmithKline that grants GSK exclusive rights to develop and market recombinant erythropoietin for chronic renal anemia outside Japan
You may also be interested in...
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
BeiGene gets a new chief business executive and there are new CMOs at Cellectar Biopharma, MacroGenics and Reata Pharmaceuticals.